ArticleFrontiers in microbiology2025
Evaluation of the immune effect of foot-and-mouth disease virus-like particles derived from
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of the effectiveness of polypeptide, virus-like particles, and viral vector vaccines for foot-and-mouth disease (2020-2025).Scientific reports · 2025Pooled it
- Evolutionary and structural insights into VP1 epitopes of representative SAT-type FMDV strains: implications for candidate vaccine selection.Veterinary research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease (FMD) is an acute, highly contagious, infectious disease that affects cloven-hoofed animals and the healthy development of animal husbandry. Despite the pivotal role of the inactivated FMD vaccine in preventing and controlling the disease, the production and preparation of the inactivated vaccine still present certain safety concerns. Virus-like particles (VLPs), which have a shell structure similar to that of the viruses but lack the genetic material of viruses, have emerged as a prominent area of research on developing next-generation FMD vaccines. In this study, co-expression of P1 and 3C was implemented to obtain the capsid protein of FMD virus (FMDV), and VLPs of FMD were prepared using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.